- Status:
- Red
- Decision Date:
- March 2021
Comments
RED:
- NICE TA814: Abrocitinib, tralokinumab or upadacitinib
for treating moderate to severe atopic dermatitis. (Decision date - September 2022)
Adults commissioned by ICB. Adolescents commissioned by NHSE.
search again
